Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
By John W. Park, K. Hong, D. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, Ulrik B. Nielsen, J. Marks, Dan H. Moore and 2 more. Clinical Cancer Research, 2002
683 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/86a19bae0c10c8f8506873d9e65b213a7bc21aac
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, background): “First, when drugs and imaging agents are associated with nanoscale carriers, their volumes of distri- Table 2 Nanoscale systems for imaging Drug delivery systems Stage of development Technique Contrast agent/imaging agent/radiolabel Limitations of use References Liposomes Preclinical SPECT 99mTc Pre”
- Liposomal drug delivery systems: from concept to clinical applications. (2013, background): “[126].”
- Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. (2006, methodology): “Doxorubicin-loaded anti-HER2 immunoliposomes produced marked therapeutic results in HER2-overexpressing xenograft models, and were significantly superior to all other treatment conditions tested, including free doxorubicin, nontargeted liposomal doxorubicin, recombinant anti-HER2 MAb trastuzumab, an”
- Interactions of nanomaterials and biological systems: implications to personalized nanomedicine (2012, background): “The increasing availability of monoclonal antibodies for targeted therapy at large has fostered the interest of antibody-functionalized targeted nanomaterial for many years [95-98].”
- Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, result): “However, significantly superior therapeutic results was demonstrated with the doxorubicin-loaded antiHER2 immunoliposomes in comparison to all other control groups, including recombinant anti-HER2 Mab trastuzumab, non-targeted liposomal doxorubicin, and free doxorubicin (Park et al., 2002).”
- Advances and Challenges of Liposome Assisted Drug Delivery (2015, unknown): “However, doxorubicin-loaded anti-HER2 immunoliposomes produced significantly superior therapeutic results in comparison to all other control groups, including free doxorubicin, nontargeted liposomal doxorubicin and recombinant anti-HER2 Mab trastuzumab (Park et al., 2002).”
- To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, unknown): “Anti-HER-2 Liposomes MCF-7 Preclinical [79]”
- Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, unknown): “F(ab′) Liposome HER2 Breast cancer [228]”
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity (2004, background): “…assessed in animals xenografted with human breast cancer cells, anti-HER2/neu PLD showed higher antitumor efficacy than DOX, reduced systemic toxicity, and the same prolonged circulation of nontargeted PLD without any apparent drug leakage or monoclonal antibody dissociation (Park et al., 2002).”
- Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles (2009, background): “(11) showed that antibody-targeted liposomes had enhanced antitumor effects as compared with their untargeted counterparts.”